Gaurav Shah

Gaurav Shah, MD, is the CEO and President of Rocket Pharmaceuticals since October 2015, focusing on developing gene-modified cell therapies for rare diseases. Additionally, Gaurav serves as a Venture Partner at RTW Investments and as a NYC Interviewer for Harvard College Admissions. From January 2011 to September 2015, Gaurav held significant roles at Novartis, including Global Program Head for CAR-T therapies, overseeing all facets of T-cell therapy from manufacturing to product launch. Gaurav's previous experience includes roles at Columbia University Medical Center, Eli Lilly, and Memorial Sloan-Kettering Cancer Center, with a strong emphasis on oncology and clinical trials. Gaurav earned a BA from Harvard University and an MD from Columbia University Vagelos College of Physicians and Surgeons.